重组人血管内皮抑素联合NP方案治疗晚期非小细胞肺癌的临床观察  

The Clinical Observation of Advanced NSCLC Treated by Recombinant Human Endostatin in Combination with NP Regimen

作　　者：顾洪兵[1] 朱亚芳[1] 谭清和[1] 陆俊国[1] 

机构地区：[1]南通市肿瘤医院化疗科,江苏南通226361

出　　处：《肿瘤基础与临床》2010年第1期54-55,共2页journal of basic and clinical oncology

摘　　要：目的观察重组人血管内皮抑素(YH-16)+NP方案治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副反应。方法54例晚期NSCLC随机分为治疗组和对照组,分别以YH-16+NP方案和安慰剂+NP方案治疗,治疗2周期后评价近期疗效和毒副反应。结果治疗组的有效率46.15%、临床获益率84.62%、中位肿瘤进展时间6.8个月均优于对照组的38.46%、76.92%、4.3个月,但两组比较差异无统计学意义(P>0.05)。结论YH-16+NP方案治疗晚期NSCLC疗效较好,毒副反应可耐受。Objective To investigate the short term efficacy and toxicities of recombinant human endostatin（YH-16） plus NP regimen in the treatment of non-small cell lung cancer（NSCLC）.Methods 54 patients with advanced NSCLC were divided into at random two groups.The treatment group were treated by YH-16 plus NP regimen;the control group were treated by placebo plus NP regimen.The short term efficacy and toxicities were evaluated two cycles after treatment.Results The response rates of the treatment group and the control group were 46.15% and 38.46% respectively（P〉0.05）;the clinical benefit rates were 84.62% and 76.92% respectively（P〉0.05）;the median time to tumor progression were 6.9 and 4.2 months respectively（P〉0.05）.Conclusion YH-16 plus NP regimen is a good regimen for patients with advanced NSCLC,and the toxicities are tolerated.

关 键 词：重组人血管内皮抑素 NP方案 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.58[医药卫生—临床医学]